Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: A prospective study

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 4, 2011, Pages 462-469

  Laharie, D ^a,b,c   Mesli, S ^c,d   El Hajbi, F ^a,b   Chabrun, E ^a,b   Chanteloup, E ^a,b   Capdepont, M ^a,b   Razaire, S ^a,b   De Ledinghen V ^a,b   Zerbib, F ^e  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d HÔPITAL PELLEGRIN   (France)

^e HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CROHN DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY;

EID: 79960560410     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04743.x     Document Type: Article

References (27)

1. Irvine EJ,. Review article: patients' fears and unmet needs in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 54-9. (Pubitemid 39319248)
2. Consigny Y, Modigliani R, Colombel JF, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006; 12: 551-7. (Pubitemid 43977735)
3. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22. (Pubitemid 30452574)
4. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-8. (Pubitemid 40299092)
5. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793-8.
6. Konikoff MR, Denson LA,. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 524-34.
7. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008; 103: 2007-14.
8. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190-8.
9. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010; 22: 340-5.
10. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010; 4: 144-52.
11. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40-6. (Pubitemid 351196867)
12. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-9.
13. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
14. Rutgeerts P,. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease. First results of the EXTEND trial. Gastroenterology 2009; 136 (Suppl. 1): A-116.
15. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29.
16. Sipponen T, Bjorkesten CG, Farkkila M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010; 45: 325-31.
17. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
18. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
19. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53. (Pubitemid 43764536)
20. Kolho KL, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006; 41: 720-5. (Pubitemid 43995015)
21. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-60. (Pubitemid 34827189)
22. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009; 104: 673-8.
23. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15: 1851-8.
24. Lemann M, Colombel JF, Grimaud JC, et al. Fecal calprotectin and high sensitivity C-reactive protein levels to predict mucosal healing in patients with Crohn's disease. A subanalysis of the STORI study. Gut 2010; 59: OP370.
25. Costes L, Colombel JF, Mary JY, et al. Long term follow up of a cohort of steroid dependant Crohn's disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine. Gastroenterology 2008; 134: A134.
26. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7. (Pubitemid 351284485)
27. Moum B, Jahnsen J, Bernklev T,. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 2010; 16: 1091-2.